Literature DB >> 12542485

A novel fusion variant of the MORF and CBP genes detected in therapy-related myelodysplastic syndrome with t(10;16)(q22;p13).

Kensuke Kojima1, Kinuyo Kaneda, Chikamasa Yoshida, Hirokata Dansako, Nobuharu Fujii, Tomofumi Yano, Katsuji Shinagawa, Masaki Yasukawa, Shigeru Fujita, Mitsune Tanimoto.   

Abstract

We report a case of therapy-related myelodysplastic syndrome (t-MDS) with t(10;16)(q22;p13), in which novel fusion transcripts of the MORF and CBP genes were detected. In one MORF-CBP fusion transcript, exon 15 of the MORF gene was fused in frame with exon 5 of the CBP gene. In a reciprocal CBP-MORF transcript, exon 4 of the CBP gene was fused in frame with exon 16 of the MORF gene. This is the first reported case of t-MDS associated with t(10;16), and provides molecular evidence that the novel MORF-CBP and/or CBP-MORF fusion protein(s) might play an important role in the development of t-MDS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12542485     DOI: 10.1046/j.1365-2141.2003.04059.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  12 in total

Review 1.  Protein lysine acetylation by p300/CBP.

Authors:  Beverley M Dancy; Philip A Cole
Journal:  Chem Rev       Date:  2015-01-16       Impact factor: 60.622

Review 2.  Gain-of-function mutation of chromatin regulators as a tumorigenic mechanism and an opportunity for therapeutic intervention.

Authors:  Chen Shen; Christopher R Vakoc
Journal:  Curr Opin Oncol       Date:  2015-01       Impact factor: 3.645

3.  The overexpression of MYST4 in human solid tumors is associated with increased aggressiveness and decreased overall survival.

Authors:  Chao-Lien Liu; Jim Jinn-Chyuan Sheu; Hsuan-Ping Lin; Yung-Ming Jeng; Cherry Yin-Yi Chang; Chih-Mei Chen; Jack Cheng; Tsui-Lien Mao
Journal:  Int J Clin Exp Pathol       Date:  2019-02-01

4.  Disruption of the histone acetyltransferase MYST4 leads to a Noonan syndrome-like phenotype and hyperactivated MAPK signaling in humans and mice.

Authors:  Michael Kraft; Ion Cristian Cirstea; Anne Kathrin Voss; Tim Thomas; Ina Goehring; Bilal N Sheikh; Lavinia Gordon; Hamish Scott; Gordon K Smyth; Mohammad Reza Ahmadian; Udo Trautmann; Martin Zenker; Marco Tartaglia; Arif Ekici; André Reis; Helmuth-Guenther Dörr; Anita Rauch; Christian Thomas Thiel
Journal:  J Clin Invest       Date:  2011-08-01       Impact factor: 14.808

5.  Crebbp haploinsufficiency in mice alters the bone marrow microenvironment, leading to loss of stem cells and excessive myelopoiesis.

Authors:  Stephanie N Zimmer; Qing Zhou; Ting Zhou; Ziming Cheng; Sherry L Abboud-Werner; Diane Horn; Mike Lecocke; Ruth White; Andrei V Krivtsov; Scott A Armstrong; Andrew L Kung; David M Livingston; Vivienne I Rebel
Journal:  Blood       Date:  2011-05-09       Impact factor: 22.113

Review 6.  The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases.

Authors:  Xiang-Jiao Yang
Journal:  Nucleic Acids Res       Date:  2004-02-11       Impact factor: 16.971

7.  Therapy related acute myeloid leukemia with t(10:16): a rare entity.

Authors:  Guldeep K Uppal; John Leighton; Deline Da Costa; Andrew Czulewicz; Irma E Palazzo
Journal:  Hematol Rep       Date:  2011-12-15

Review 8.  The KAT6B-related disorders genitopatellar syndrome and Ohdo/SBBYS syndrome have distinct clinical features reflecting distinct molecular mechanisms.

Authors:  Philippe M Campeau; James T Lu; Brian C Dawson; Ivo F A C Fokkema; Stephen P Robertson; Richard A Gibbs; Brendan H Lee
Journal:  Hum Mutat       Date:  2012-07-12       Impact factor: 4.878

Review 9.  Mechanisms of epigenetic regulation of leukemia onset and progression.

Authors:  Panagiotis Ntziachristos; Jasper Mullenders; Thomas Trimarchi; Iannis Aifantis
Journal:  Adv Immunol       Date:  2013       Impact factor: 3.543

10.  MOZ-TIF2 repression of nuclear receptor-mediated transcription requires multiple domains in MOZ and in the CID domain of TIF2.

Authors:  Hong Yin; Jonathan Glass; Kerry L Blanchard
Journal:  Mol Cancer       Date:  2007-08-13       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.